TRACES pilot pharmacokinetic study

This dataset summarizes raw data used to build the pharmacokinetic model described in Gilliot et al. The dataset was designed to be ready to be analyzed by the software MONOLIX 2019R1 (Lixoft, Orsay, France). Patients were included if they were undergoing haemorrhagic cesarean section (blood loss > 800 mL) and receiving a single i.v dose of TA (0.5, 1 or 2 g over 1 minute). Non-inclusion criteria used were presented in the TRACES pilot study protocol.[1] The first seven columns on the left of the dataset describe the pharmacokinetic data. The blood TDM samples were obtained from our patients at T0 (inclusion time, when bleeding ≥ 800 mL is diagnosed), T1 (at the end of injection), T15, T30, T60, T120, T180, and T360 (defined as 15, 30, 60, 120, 180 and 360 min after the injection). The urinary samples were collected within 6 hours after treatment. From the eight column, the variables describe the anthropometric, biological and clinical characteristics of the patients included in the study. Vs1 represents the volume of blood loss at the inclusion time in L. SCr1 represents the serum creatinine at inclusion time and SCr2 represents the serum creatinine 360 after the administration of tranexamic acid, in mg/L. Uremia is expressed in g/L.